Aquinox Pharmaceuticals, Inc. (AQXP) Downgraded by Zacks Investment Research to “Hold”
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
A number of other equities analysts also recently commented on the company. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 8th. BidaskClub raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. ValuEngine raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Cantor Fitzgerald set a $28.00 target price on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, May 9th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $22.25.
Aquinox Pharmaceuticals (NASDAQ AQXP) traded up 5.02% during mid-day trading on Tuesday, reaching $14.02. The company’s stock had a trading volume of 66,720 shares. The firm’s market capitalization is $328.39 million. The stock’s 50-day moving average is $14.44 and its 200-day moving average is $15.39. Aquinox Pharmaceuticals has a 12 month low of $8.76 and a 12 month high of $19.97.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.59). On average, equities analysts anticipate that Aquinox Pharmaceuticals will post ($2.15) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/15/aquinox-pharmaceuticals-inc-aqxp-downgraded-by-zacks-investment-research-to-hold.html.
In other Aquinox Pharmaceuticals news, insider David Main sold 15,625 shares of the firm’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $13.26, for a total value of $207,187.50. Following the transaction, the insider now owns 77,530 shares of the company’s stock, valued at $1,028,047.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.70% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Nexthera Capital LP acquired a new position in shares of Aquinox Pharmaceuticals during the second quarter worth about $1,276,000. Sphera Funds Management LTD. acquired a new position in shares of Aquinox Pharmaceuticals during the second quarter worth about $874,000. Vanguard Group Inc. boosted its position in shares of Aquinox Pharmaceuticals by 6.6% in the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock worth $3,974,000 after buying an additional 17,455 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Aquinox Pharmaceuticals by 10.0% in the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock worth $2,028,000 after buying an additional 11,035 shares in the last quarter. Finally, Investment Centers of America Inc. acquired a new position in shares of Aquinox Pharmaceuticals during the first quarter worth about $172,000. 98.20% of the stock is currently owned by hedge funds and other institutional investors.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.